Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
FGEN is in the long-term up 116% in 4 years.
Description: FibroGen, Inc. discovers, develops, and commercializes drugs for anemia and pulmonary fibrosis. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was founded in 1993 and is headquartered in San Francisco, California.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||19.29%||Sales Growth - Q/Q||1.2%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-31.33%||ROE||-73.92%||ROI||-45.95%|
|Current Ratio||2.88||Quick Ratio||Long Term Debt/Equity||0.95||Debt Ratio||0.29|
|Gross Margin||Operating Margin||-281.76%||Net Profit Margin||-296.24%||Dividend Payout Ratio|
|Cash From Financing Activities||620 K||Cash From Investing Activities||4.55 M||Cash From Operating Activities||-42.19 M||Gross Profit|
|Net Profit||-46.37 M||Operating Profit||-44.72 M||Total Assets||435.54 M||Total Current Assets||155.4 M|
|Total Current Liabilities||53.96 M||Total Debt||111.65 M||Total Liabilities||250.92 M||Total Revenue||16.3 M|
|High 52 week||67.25||Low 52 week||37.97||Last close||58.53||Last change||2.65%|
|RSI||58.24||Average true range||1.95||Beta||1.53||Volume||241.17 K|
|Simple moving average 20 days||3.09%||Simple moving average 50 days||16.53%||Simple moving average 200 days||8.85%|
|Performance Week||0.05%||Performance Month||9.48%||Performance Quart||48.63%||Performance Half||-5.29%|
|Performance Year||4.15%||Performance Year-to-date||26.47%||Volatility daily||1.98%||Volatility weekly||4.42%|
|Volatility monthly||9.06%||Volatility yearly||31.39%||Relative Volume||223.58%||Average Volume||638.76 K|
|New High||New Low|
2019-04-10 10:30:02 | Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
2019-04-08 15:38:18 | Is FibroGen, Inc. NASDAQ:FGEN A Financially Strong Company?
2019-04-03 10:48:02 | Options Traders Expect Huge Moves in FibroGen FGEN Stock
2019-04-02 07:07:00 | 4 Biotech Stocks With Major Catalysts in April
2019-03-07 14:16:10 | FibroGen, Inc. NASDAQ:FGEN: Commentary On Fundamentals
2019-03-05 16:06:09 | What's in the Cards for Corbus CRBP This Earnings Season?
2019-03-01 13:57:16 | What Wall Street Recommends for Amarin after Q4 2018 Results
2019-03-01 06:36:49 | Edited Transcript of FGEN earnings conference call or presentation 27-Feb-19 10:00pm GMT
2019-02-28 00:45:06 | FibroGen Inc FGEN Q4 2018 Earnings Conference Call Transcript
2019-02-27 16:08:12 | FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-22 23:43:13 | FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-22 16:36:09 | What's in Store for Teladoc's TDOC Q4 Earnings?
2019-02-20 09:32:02 | Tenet Healthcare THC Q4 Earnings: What's in the Offing?
2019-02-08 08:03:40 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-02-06 10:50:01 | How Much is FibroGen, Inc.’s NASDAQ:FGEN CEO Getting Paid?
2019-01-29 08:04:08 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-01-17 08:01:54 | See what the IHS Markit Score report has to say about FibroGen Inc.
2019-01-17 08:00:00 | Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and FibroGen
2019-01-17 07:35:00 | Analysis: Positioning to Benefit within Motorola Solutions, FibroGen, UnitedHealth Group, Newell Brands, Vuzix, and Choice Hotels International — Research Highlights Growth, Revenue, and Consolidated Results
2019-01-09 08:03:59 | See what the IHS Markit Score report has to say about FibroGen Inc.
2018-12-20 16:14:43 | Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes
2018-12-20 09:09:00 | AstraZeneca stock up 2.8% after announcing EU approval of COPD treatment
2018-12-20 08:02:27 | See what the IHS Markit Score report has to say about FibroGen Inc.
2018-12-20 07:00:00 | Today's Research Reports on Trending Tickers: Aimmune Therapeutics and FibroGen
2018-12-19 01:21:12 | FibroGen Inc FGEN: Hedge Fund Sentiment Unchanged
2018-12-18 20:21:58 | [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time
2018-12-18 17:18:43 | Why a kidney disease drug approval in China is just the start for this S.F. company
2018-12-18 06:24:52 | China first to approve AstraZeneca, FibroGen anaemia drug
2018-12-17 12:21:09 | How Many Insiders Sold FibroGen, Inc. NASDAQ:FGEN Shares?
2018-12-06 04:00:00 | FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors
2018-11-27 08:45:00 | New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018
2018-11-24 08:05:47 | See what the IHS Markit Score report has to say about FibroGen Inc.
2018-11-22 08:05:55 | See what the IHS Markit Score report has to say about FibroGen Inc.
2018-11-14 06:55:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen
2018-11-13 08:05:56 | See what the IHS Markit Score report has to say about FibroGen Inc.
2018-11-09 03:17:07 | Edited Transcript of FGEN earnings conference call or presentation 8-Nov-18 10:00pm GMT
2018-11-08 18:40:11 | FibroGen FGEN Reports Q3 Loss, Lags Revenue Estimates
2018-11-08 17:35:50 | FibroGen: 3Q Earnings Snapshot
2018-11-08 16:02:00 | FibroGen Reports Third Quarter 2018 Financial Results
2018-11-06 08:02:22 | See what the IHS Markit Score report has to say about FibroGen Inc.
2018-11-05 13:55:56 | What Kind Of Shareholder Appears On The FibroGen Inc’s NASDAQ:FGEN Shareholder Register?
2018-11-02 17:02:51 | FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018
2018-10-25 19:49:27 | FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting
2018-10-18 08:00:00 | Today's Research Reports on Trending Tickers: Immunomedics and FibroGen